{"id":"W4403176298","doi":"10.1016/s1473-3099(24)00499-7","title":"Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"Nosocomial Infections in ICU","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"Innovative Medicines Initiative; Innovative Health Initiative; Pfizer","keywords":"Aztreonam; Descriptive statistics; Gram-negative bacteria; Ceftazidime/avibactam; Open label; Medicine; Gram; Meropenem; Internal medicine; Randomized controlled trial; Microbiology; Bacteria; Biology; Statistics; Antibiotics; Mathematics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002697656,0.002320451,0.004549779,0.0004853029,0.0005490234,0.001639575,0.001226263,0.002457679,0.007663161],"category_scores_gemma":[0.003241003,0.0008305272,0.004597733,0.0004691008,0.001637557,0.00187797,0.000642721,0.003646687,0.001089013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009156787,"about_ca_system_score_gemma":0.0009623056,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0013992,"about_ca_topic_score_gemma":0.002995605,"domain_scores_codex":[0.9987997,0.0007011355,0.00008691568,0.0001899396,0.00007063594,0.0001516636],"domain_scores_gemma":[0.9983141,0.0007308308,0.0003619709,0.0001705915,0.0001001784,0.0003221853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9895924,0.001385397,0.0001746069,0.0007725908,0.001133328,0.00002362105,0.00004460582,0.0001483054,0.001176776,0.00007867446,0.0003124315,0.005157197],"study_design_scores_gemma":[0.973455,0.02459012,0.0005853967,0.00005586424,0.0005868872,0.00002155283,0.00002186165,0.0001616831,0.0001122448,0.0001045935,0.0002913736,0.0000135184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9711025,0.01594151,0.001427983,0.001314195,0.001464629,0.004391124,0.001611219,0.0001757494,0.00257115],"genre_scores_gemma":[0.9763274,0.006807003,0.002874873,0.001976187,0.0009669494,0.00494551,0.001494703,0.00005719827,0.00455029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007663161,"threshold_uncertainty_score":0.02563584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08018690272348557,"score_gpt":0.3962698453132819,"score_spread":0.3160829425897963,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}